Polomar Health Services Inc (OTC: PMHS) is a specialty pharmacy company that compounds and dispenses prescription medications, with operations concentrated in dermatological formulations and GLP-1 agonist therapies. Revenue is generated on a transactional basis through prescription fulfillment for dermatologists and, as of October 2025, through a one-year non-exclusive pharmacy services agreement with CareValidate, Inc. to fulfill GLP-1 agonist prescriptions for CareValidate's network of online clinics. As of December 31, 2025, the company had six full-time and two part-time employees across offices in Florida, California, and New York. The company entered into an Agreement and Plan of Merger with Altanine, Inc. dated July 23, 2025, which, upon closing, would install Altanine's CEO Charles Andres, Jr. as CEO of the combined company and reconstitute the board with four Altanine appointees. The filing discloses material weaknesses in internal controls, including inadequate segregation of duties and insufficient written accounting policies, and the company carries convertible promissory note debt including a CWR Note II with a 12% APR issued July 21, 2025.

Revenue model

Transactional prescription fulfillment fees from compounded dermatological and sterile GLP-1 agonist medications, including under a one-year non-exclusive pharmacy services agreement with CareValidate, Inc. executed September 26, 2025.

Products and services

Compounded dermatological prescription medications for topical delivery targeting acne, alopecia areata, basal cell carcinoma, Becker's nevus, vitiligo, and other skin conditions. Sterile compounded GLP-1 agonist drugs for subcutaneous injection, fulfilled under a Special Sterile Compounding Permit received August 2024. A Product Fulfillment and Distribution Agreement with Island 40 Group, LLC was also referenced in the filing (executed March 17, 2025).

Customers and end markets

Local dermatologists and their patients for compounded dermatological drugs. CareValidate, Inc.'s network of online clinics for GLP-1 agonist prescription fulfillment, beginning October 6, 2025. Prior business described as limited interstate prescription delivery.

Value-chain role

Specialty compounding pharmacy operating as a downstream prescription fulfillment provider; co-develops dermatological formulations with board-certified dermatologists and holds a Special Sterile Compounding Permit for sterile drug dispensing.

Geographic exposure

United States, with offices in Florida, California, and New York as of December 31, 2025. Prior pharmacy operations described as primarily local with limited interstate delivery.

Source: SEC 10-K, filed 2026-05-06

Industry: Pharmaceutical Preparations